- Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
- Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
- Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
- Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
- Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Wednesday, Eledon Pharmaceuticals Inc (ELDN:NAQ) closed at 2.46, -26.55% below its 52-week high of 3.35, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.45 |
---|---|
High | 2.52 |
Low | 2.41 |
Bid | 2.44 |
Offer | 2.59 |
Previous close | 2.41 |
Average volume | 157.84k |
---|---|
Shares outstanding | 38.51m |
Free float | 37.16m |
P/E (TTM) | -- |
Market cap | 94.73m USD |
EPS (TTM) | -1.41 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼